Example 3
[Pharmaceutical Product]

Objective:

a) The objective of this project is to locate published patent applications/patents and non-patent literature which are published before date of priority of US Patent No. **9,205,052B2** and **9,192,575 B2** in order to invalidate the claimed invention therein.

b) To conduct patent landscape for postoperative analgesia.

Drug: Bupivacaine HCl

Search Strategy- Patent No. 9,205,052B2

- **Key Features:**

  Key Feature 1- Local anesthesia
  Key Feature 2 - Administering a single dose
  Key Feature 3 - Multivesicular liposome
  Key Feature 4 - Bupivacaine phosphate

- **IPC class:**

  A61K: PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J 3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D).

  A61K 9/127: Liposomes

Results

YASHAM

EPIDURAL ADMINISTRATION OF THERAPEUTIC COMPOUNDS WITH SUSTAINED RATE OF RELEASE

Claims of US6428529 (B1)

A high quality text as facsimile in your desired language may be available amongst the following family members:

AU699177 (B2) CA2226870 (A1) EP0839027 (A4) JPH11508900 (A) MX9800391 (A) NO326261 (B1)
RU2215522 (C2) WO9703652 (A1) EP2036542 (A1) JP2008143911 (A) JP2010031030 (A) JP2010043104 (A)

Translate this text into

Albanian

patenttranslate powered by EPO and Google

Original claims | **Claims tree**

The EPO does not accept any responsibility for the accuracy of data and information originating from other authorities than the EPO; in particular, the EPO does not guarantee that they are complete, up-to-date or fit for specific purposes.

What is claimed is:

1. A method for epidural administration to a vertebrate of a therapeutic compound comprising encapsulating a therapeutic compound in a drug delivery system having a sustained release rate of the compound from about 2 to about 7 days, and introducing the drug delivery system in a single epidural dose to the vertebrate, wherein the drug delivery system comprises multivesicular liposomes produced from the group consisting of egg phosphatidylcholines, dipalmitoylphosphatidylcholines, distearoylphosphatidylcholines, dioleoylphosphatidylcholines, dipalmitoylphosphatidylglycerols, dioleoyl-phosphatidylglycerols, and suitable combinations thereof.

2. The method of claim 1 wherein the multivesicular liposomes further comprise at least one steroid.

Claims:

1. A method for epidural administration to a vertebrate of a therapeutic compound comprising encapsulating a therapeutic compound in a drug delivery system having a sustained release rate of the **compound from about 2 to about 7 days**, and introducing the drug delivery system in a single epidural dose to the vertebrate, wherein the drug delivery system comprises **multivesicular liposomes** produced from the group consisting of egg phosphatidylcholines, dipalmitoylphosphatidylcholines, distearoylphosphatidylcholines, dioleoylphosphatidylcholines, dipalmitoylphosphatidylglycerols, dioleoyl-phosphatidylglycerols, and suitable combinations thereof.

YASHAM

Modulation of drug loading in multivescular liposomes

Page bookmark	US6106858 (A) - Modulation of drug loading in multivescular liposomes
Inventor(s):	YE QIANG [US]; KATRE NANDINI [US]; SANKARAM MANTRIPRAGADA [US] +
Applicant(s):	SKYEPHARMA INC [US] +
Classification:	- international: *A61K31/485; A61K31/7068; A61K38/04; A61K38/22; A61K38/24; A61K45/00; A61K47/04; A61K47/06; A61K47/10; A61K47/12; A61K47/14; A61K47/16; A61K47/18; A61K47/26; A61K47/36; A61K9/127; A61P11/06; A61P23/00; A61P25/04; A61P25/20; A61P25/22; A61P29/00; A61P3/10; A61P31/10; A61P31/12; A61P35/00; A61P37/02; A61P5/00; A61P9/00; A61P9/04; A61P9/06; A61P9/12;* (IPC1-7): A61K9/127
	- cooperative: A61K9/127
Application number:	US19970925532 19970908
Priority number(s):	US19970925532 19970908

Description:
Col. 10, lines 43-45
Representative examples of anti-nociceptives useful in the compositions and methods of the present invention include **bupivacaine**, hydromorphine, oxycodone, fentanyl, morphine, and meperidine.

19. **A process for controlling loading of at least one biologically active agent into multivesicular liposomes** having multiple non-concentric chambers with membranes distributed as a continuous network throughout comprising the steps of:
a) forming a standard first immiscible component by dissolving at least one biologically active agent in a first aqueous solution and then measuring the osmolarity;